Publication | Closed Access

The potential for efficacy of the modified (ICP 34.5−) herpes simplex virus HSV1716 following intratumoural injection into human malignant glioma: a proof of principle study

Neuro-oncologyCancer-associated VirusImmunologyPrinciple StudyPathologyHerpesvirusesViral OncologyRadiation OncologyMedicineGliomaIcp 34.5−Intratumoural InjectionHerpes Simplex Virus Vaccines